Teicoplanin EBERTH
dosage/strength | dosage form | pack size |
| pharmaceutical registration number | SmPC |
|---|---|---|---|---|---|
200 mg | Powder for concentrate for solution for injection / infusion or for oral solution | 1 vial | N1 | 17582874 |  |
400 mg | Powder for concentrate for solution for injection / infusion or for oral solution | 1 vial | N1 | 17582880 |
Active substance:
Teicoplanin
Pharmacotherapeutic group:
Glycopetide
ATC code: J01XA02
Mechanism of action:
Teicoplanin inhibits the growth of susceptible organisms by influencing cell wall synthesis at a point of attack that differs from that of beta-lactams. The peptidoglycan synthesis is blocked because of specific binding to D-alanyl-D-alanine residues.
Therapeutic indications:
Teicoplanin Eberth is indicated in adults and children from birth on for the parenteral treatment of the following infections:
- Complicated skin and soft tissue infections
- Bone and joint infections
- Nosocomial pneumonia
- Community acquired pneumonia
- Complicated urinary tract infections
- Infectious endocarditis
- Peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD)
- Bacteremia that occurs as part of any of the indications listed above
Teicoplanin Eberth is also indicated for oral use as an alternative treatment for diarrhea and colitis caused by infection with Clostridioides difficile.
Teicoplanin Eberth should, if necessary, be used in combination with other antibacterial drugs.